Eton Pharmaceuticals (NASDAQ:ETON) Given New $17.00 Price Target at HC Wainwright

Eton Pharmaceuticals (NASDAQ:ETON) had its price objective hoisted by HC Wainwright from $15.00 to $17.00 in a report issued on Monday, Marketbeat.com reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ FY2027 earnings at $1.27 EPS, FY2028 earnings at $1.62 EPS and FY2029 earnings at $2.31 EPS.

Separately, Craig Hallum raised their price target on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a report on Monday, October 28th.

Eton Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:ETON opened at $12.01 on Monday. Eton Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $15.00. The firm has a market cap of $312.87 million, a P/E ratio of -54.59 and a beta of 1.38. The company’s 50-day moving average price is $11.57 and its two-hundred day moving average price is $7.32.

Institutional Trading of Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ETON. Wasatch Advisors LP acquired a new position in Eton Pharmaceuticals during the 3rd quarter valued at about $1,431,000. Thompson Siegel & Walmsley LLC acquired a new position in Eton Pharmaceuticals in the second quarter valued at approximately $420,000. Aristides Capital LLC bought a new position in Eton Pharmaceuticals in the second quarter valued at approximately $658,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after acquiring an additional 30,167 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Eton Pharmaceuticals by 63.8% during the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock worth $350,000 after acquiring an additional 41,469 shares during the period. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.